A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Researchers have developed a new class of antibodies that amplify the immune system’s ability to fight cancer. By clustering ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...